Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations

Multiple Cancer Types

Leukemia, Pediatric Leukemia, Pediatrics
III
Zarnegar-Lumley, Sara
NCT04293562
COGAAML1831


A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Multiple Cancer Types

Germ Cell (Pediatrics), Gynecologic, Ovarian
III
Borinstein, Scott
NCT03067181
COGAGCT1531

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Multiple Cancer Types

Neuroblastoma (Pediatrics), Pediatrics
III
Benedetti, Daniel
NCT03126916
COGANBL1531

Phase 3 Accelerated BEP Trial: A Randomised Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumours

Germ Cell (Pediatrics)

Germ Cell (Pediatrics)
III
Borinstein, Scott
NCT02582697
COGAGCT1532

International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones

Multiple Cancer Types

Pediatric Leukemia, Pediatrics
III
Zarnegar-Lumley, Sara
NCT03007147
COGAALL1631

Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

Multiple Cancer Types

Hepatoblastoma (Pediatrics), Pediatric Solid Tumors, Pediatrics
II/III
Benedetti, Daniel
NCT03533582
COGAHEP1531

Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Multiple Cancer Types

Pediatrics, Wilms / Other Kidney (Pediatrics)
II
Benedetti, Daniel
NCT04322318
COGAREN1921

A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to <31 Years Old with First Relapse

Multiple Cancer Types

Pediatric Leukemia, Pediatrics
II
Zarnegar-Lumley, Sara
NCT04546399
COGAALL1821

Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma

Multiple Cancer Types

Pediatrics, Sarcoma
II
Borinstein, Scott
NCT04388839
VICCPED2134

To learn more about any of our clinical
trials, call 615-936-8422.